Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Pfizer to use Covid and divestment cash to power growth
View:
Post by Noteable on Jul 13, 2022 4:24pm

Pfizer to use Covid and divestment cash to power growth

Pfizer is in a unique position in its history with gushers of cash flowing in from everywhere. Pfizer will use this cash to power future growth through its drug pipeline, innovation, and acquisitions, which will secure promising returns and profitability for investors in the year ahead. 

Not only is Pfizer is generating significant sums of cash from its COVID-19 vaccine, these sums will only increase with the planned listing of the consumer healthcare business that is owned jointly between Pfizer (32%) and GSK (68%). Pfizer had indicated its intention to sell its stake through the listing, which could generate up to $19 billion in proceeds.
Comment by IFlyTheUnicorn on Jul 14, 2022 12:25am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities